AC Immune S.A.
ACIUNASDAQHealthcare● Active
$2.21
$-0.05(-2.00%)
Market Cap$224410721
P/E Ratio—
52W High$4
52W Low$1.65
AC Immune S.A. (ACIU) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ACIU · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.57M | $27.31M | $14.80M | $3.94M | $0.00M |
| Cost of Revenue | $0.00M | $62.57M | $54.61M | $0.00M | $0.00M |
| Gross Profit | $3.57M | ($35.26M) | ($39.80M) | $3.94M | $0.00M |
| Gross Margin %(computed) | 100.00% | -129.12% | -268.93% | 100.00% | — |
| Operating Expenses | |||||
| R&D Expenses | $56.44M | $62.57M | $54.61M | $60.34M | $62.28M |
| G&A Expenses | $11.65M | $11.43M | $10.58M | $9.58M | $10.88M |
| Total Operating Expenses | $72.44M | $17.12M | $13.82M | $74.78M | $79.01M |
| Operating Income | ($68.86M) | ($52.38M) | ($53.62M) | ($70.85M) | ($79.01M) |
| Operating Margin %(computed) | — | -191.80% | -362.30% | — | — |
| Interest Income | $1.86M | $3.20M | $1.04M | $0.07M | $6.49M |
| Interest Expense | $0.19M | $0.13M | $0.18M | $0.35M | $0.58M |
| Income Before Tax | ($70.45M) | ($50.91M) | ($54.22M) | ($70.74M) | ($72.99M) |
| Income Tax Expense | $0.00M | $0.00M | $0.01M | $0.01M | $0.00M |
| Net Income | ($70.45M) | ($50.92M) | ($54.23M) | ($70.75M) | ($73.00M) |
| Net Margin %(computed) | — | -186.44% | -366.41% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.70 | $-0.51 | $-0.64 | $-0.85 | $-0.97 |
| Wtd Avg Shares | 100.75M | 99.69M | 84.69M | 83.55M | 74.95M |
| EBITDA | ($67.75M) | ($48.62M) | ($51.83M) | ($68.03M) | ($70.01M) |
| EBITDA Margin %(computed) | — | -178.03% | -350.19% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · CHF · M
Explore more AC Immune S.A. data
About AC Immune S.A. (ACIU) Income Statement
AC Immune S.A. (ACIU) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ACIU reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.07B) — a net profit margin of -1971.65%.
Frequently asked questions
ACIU · 4 questionsAC Immune S.A. (ACIU) reported revenue of $0.00B for 2025, down 86.9% year-over-year.
ACIU revenueACIU salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08